Systemic cancer immunotherapy with Toll-like receptor 7 agonists: Timing is everything

    loading  Checking for direct PDF access through Ovid

Abstract

Toll-like receptor (TLR) 7 agonists represent a promising strategy for the immunotherapy of cancer. We have recently investigated the influence of TLR tolerance on the efficacy of systemic tumor treatment with TLR7 ligands. We propose that considering the kinetics of receptor sensitivity highly improves the outcome of cancer immunotherapy.

Related Topics

    loading  Loading Related Articles